Associated Papers
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A et al.
Neuro-oncology, 2019
Select a paper to view details
Pemov A et al.
Neuro-oncology, 2019